Evidence map›Paper›PMID 19537782›Full record

ArticleAccounts of chemical research2009

Bioresponsive, cell-penetrating, and multimeric MR contrast agents.

Jody L Major, Thomas J Meade

Abstract read
In one paragraph

Article in Accounts of chemical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 316 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Energy loss function of samarium.Scientific reports · 2023
    Article
  15. Unprecedented Relaxivity Gap in pH-Responsive FeAngewandte Chemie (International ed. in English) · 2023
    Article
  16. Review
  17. c-Met-TargetingInternational journal of nanomedicine · 2023
    Article
  18. MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022
    Review
  19. Magnetic, biocompatible FeCOJournal of nanobiotechnology · 2022
    Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jody L MajorDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208-3113, USA.
Thomas J Meade
Northwestern University · US

Funding

TiO2 nanocomposites for Targeted Treatment and Imaging of Prostate cancerU54CA119341 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MIRKIN, CHAD A. · 2005 to 2009
$19.9M
q-Modulated Magnetic Resonance Imaging Contrast AgentsR01EB005866 · NIBIB · NORTHWESTERN UNIVERSITY · PI MEADE, THOMAS J · 2005 to 2013
$2.2M
NCI NIH HHS 5 U54 CA1193 41-02NCI NIH HHS U54 CA119341NIBIB NIH HHS 1 R01 EB005866-01NIBIB NIH HHS R01 EB005866
6 · The paper itself

Abstract

Magnetic resonance imaging (MRI) has become increasingly popular in experimental molecular imaging and clinical radiology because it is non-invasive and capable of producing three-dimensional representations of opaque organisms with high spatial and temporal resolution. Approximately 35% of all clinical MR scans utilize contrast media, however a primary limitation of MR imaging is the sensitivity of contrast agents that require high concentrations (0.1-0.6 mM). A number of strategies have been employed to amplify the observed in vivo signal of MR contrast agents. Approaches include attachment of Gd(III) chelates to polymers, proteins and particles, encapsulation into micelles and caged structures, and targeting to receptors. While each of these approaches has yielded significant increases in the relaxivity of MR contrast agents (and therefore sensitivity), all of these classes of complexes possess intrinsic background signal and function solely as anatomical reporters. In order to reduce the background signal and simultaneously create probes that are modulated by biochemical processes, caged complexes were designed to coordinatively saturate the paramagnetic ion. Coupled with amplification strategies, these agents represent a means to selectively modulate the observed MR signal and function as in vivo biochemical reporters. For example, to create an in vivo MR assay of enzymatic activities and secondary messengers, agents have been designed and synthesized with removable protection groups that largely prevent access of water to a paramagnetic center. By limiting the access of bulk water (q-modulation) the unprocessed agent is designed to be an ineffective contrast agent, and hence serves as a reliable marker for regions of enzyme activity or the presence of secondary messengers. Further, we have focused on designing multimodal contrast agents that are simultaneously detectable by more than one imaging technique. For example, attaching an optical probe to a MR contrast agent provides the means to detect the probe in a whole animal and subsequently validate the results by histological methods. Finally, we describe strategies for signal amplification, and cell delivery vehicles attached to imaging probes for in vivo long-term fate mapping experiments.

Indexed as

Cell Membrane PermeabilityMagnetic Resonance ImagingAmino Acid SequenceAnimalsbeta-GalactosidaseCell LineChelating AgentsContrast MediaGadoliniumImage EnhancementMagneticsMiceNIH 3T3 Cellsbeta-GalactosidaseChelating AgentsContrast MediaGadolinium

Identifiers

PMID19537782
PMCPMC2739617
OpenAlexW1992834159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.